ICCM
IceCure Medical Ltd
ICCM's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ICCM overall, supported by stronger fundamentals and stronger valuation.
ICCM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ICCM's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICCM PE Valuation
ICCM has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ICCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ICCM's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ICCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.76 | +$1.62 |
| Q1 2026 | -$7.02 | +$1.52 |
| Q4 2025 | -$7.15 | +$1.79 |
| Q3 2025 | -$7.82 | +$0.77 |
| Q2 2025 | -$8.38 | +$0.47 |
| Q1 2025 | -$8.54 | +$0.99 |
| Q4 2024 | -$8.94 | +$0.67 |
| Q3 2024 | -$8.59 | +$2.25 |
ICCM is still losing money, but far less than before: $6.76 per share over the past year, against $14.07 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ICCM on earnings quality, reporting a profit while its opponent remains loss making.
ICCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $907K | +73% |
| Q1 2026 | $911K | +26% |
| Q4 2025 | $1.3M | +46% |
| Q3 2025 | $850K | +28% |
| Q2 2025 | $525K | -48% |
| Q1 2025 | $725K | -2.4% |
| Q4 2024 | $875K | -30% |
| Q3 2024 | $662K | +102% |
ICCM's revenue is recovering but still below its 2021 peak: $907,000 last quarter, up 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 488% | +1133 points |
| Q1 2026 | -466% | +38 points |
| Q4 2025 | -330% | +188 points |
| Q3 2025 | -2108% | -1460 points |
| Q2 2025 | -645% | -326 points |
| Q1 2025 | -504% | -13 points |
| Q4 2024 | -517% | -245 points |
| Q3 2024 | -648% | +612 points |
ICCM has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ICCM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ICCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | -$1.1M |
| Q1 2026 | -$4.3M | -$277K |
| Q4 2025 | -$5.5M | -$1.3M |
| Q3 2025 | -$2.7M | +$477K |
| Q2 2025 | -$2.8M | -$464K |
| Q1 2025 | -$4M | -$1.2M |
| Q4 2024 | -$4.2M | -$1.6M |
| Q3 2024 | -$3.2M | +$209K |
ICCM has burned cash in almost every quarter: −$16M over the past year, against −$14M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ICCM on cash generation, producing positive trailing cash flow while its opponent burns cash.
ICCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +634K shares |
| 1 year | +58% | +1.1M shares |
| 3 years | +103% | +1.6M shares |
| 5 years | +223% | +2.1M shares |
| Available history | +554% | +2.6M shares |
ICCM has 3M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ICCM hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ICCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ICCM Net Leverage
ICCM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ICCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.3 | Oversold |
| Stochastic | 1.5 | Oversold |
ICCM's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ICCM PE vs Healthcare Sector
ICCM has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ICCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 36% below |
| 20 week MA | $2.23 | 69% below |
| 50 week MA | $9.11 | 92% below |
| 100 week MA | $20.4 | 97% below |
| 200 week MA | $25.3 | 97% below |
ICCM is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ICCM on trend strength, trading above more of its moving averages.
ICCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $331.5 | $85.2 | -74% |
| 2022 | $85.2 | $42.0 | -51% |
| 2023 | $42.0 | $32.1 | -24% |
| 2024 | $32.1 | $33.6 | +4.7% |
| 2025 | $33.6 | $19.9 | -41% |
| 2026 YTD | $19.9 | $0.70 | -96% |
ICCM has finished lower in four of the last five years. It's down 96% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ICCM on returns for 2026, with the stronger performance.